medigraphic.com
ISSN 0016-3813 (Impreso)

2015, Número 4

<< Anterior Siguiente >>

Gac Med Mex 2015; 151 (4)


Necrólisis epidérmica tóxica (NET) y desarrollo de abscesos hepáticos

Domínguez-Borgúa A, González I, Morales L, Martínez-Carrillo FM, Palacios P

Idioma: Español
Referencias bibliográficas: 26
Paginas: 512-518
Archivo PDF: 265.28 Kb.


RESUMEN

La hipersensibilidad a los fármacos comúnmente se manifiesta en la piel. El síndrome de Stevens-Johnson y la NET son las entidades de mayor mortalidad generalmente asociadas a antibióticos y anticonvulsivantes. La NET se asocia a la hipersensibilidad por fármacos en el 80% de los casos y puede tener repercusiones sistémicas; se ha descrito afección hepática, pero no se ha reportado la aparición de abscesos hepáticos dentro de las lesiones. Se presenta el caso de una paciente con un desarrollo acelerado de múltiples abscesos hepáticos en el contexto de hipersensibilidad a lamotrigina, así como la discusión de sus probables etiologías y su manejo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. French LE. Toxic epidermal necrolysis and Steven Jonhnson syndrome: our current understanding. Allergol Int. 2006;55(1):9-16.

  2. Endorf FW, Cancio LC, Gibran NS. Toxic epidermal necrolysis clinical guidelines. J Burn Care Res. 2008;29(5):706-12.

  3. Jean-Claude I, García DR. Necrólisis epidémica tóxica y síndrome de Stevens-Johnson: clasificación y actualidad terapéutica. Actas Dermosifiliogr. 2000;91:541-51.

  4. Serati Shirazi Z, Inaloo S. Intravenous immunoglobulin in the treatment of lamotrigine- induced toxic epidermal necrolysis. Iran J Allergy Asthma Immunol. 2008;7(4):239-41.

  5. Heneghan HM, Healy NA, Martin ST, et al. Modern management of pyogenic hepatic abscess: a case series and review of the literature. BMC Res Notes. 2011;4:80.

  6. Krige JE, Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system. BMJ. 2001;322(7285):537-40.

  7. Widgerow AD. Toxic epidermal necrolysis - management issues and treatment options. Int J Burns Trauma. 2011;1(1):42-50.

  8. Downey A, Jackson C, Harun N, Cooper A. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol. 2012;66(6):995-1003.

  9. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69(2):187.e1-16; quiz 203-4.

  10. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69(2):173.e1-13; quiz 185-6.

  11. Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis. Br J Dermatol. 2012;167(2):424-32.

  12. Quinn AM, Brown K, Bonish BK, et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol. 2005;141(6):683-7.

  13. Castelain F, Humbert P. Toxic epidermal necrolysis Curr Drug Saf. 2012;7(5):332-8.

  14. Meddings L, Myers RP, Hubbard J, et al. A population-based study of pyogenic liver abscesses in the United States: incidence, mortality, and temporal trends. Am J Gastroenterol. 2010;105(1):117-24.

  15. Molgó M, Carreño N, Hoyos-Bachiloglu R, Andresen M, González S. [Use of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis and Stevens-Johnson/toxic epidermal necrolysis overlap syndrome. Review of 15 cases]. Rev Med Chil. 2009;137(3):383-9.

  16. Laguna C, Martín B, Torrijos A, García-Melgares ML, Febrer I. Stevens- Johnson syndrome and toxic epidermal necrolysis. Actas Dermosifiliogr. 2006;97(3):177-85.

  17. Prins C, Kedel FA, Padilla S, Et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003 Jan; 139(1):26-32.

  18. Foster R, Suri A, Filate W, et al. Use of intravenous immune globulin in the ICU: a retrospective review of prescribing practices and patient outcomes. Transfus Med. 2010;20(6):403-8.

  19. Sharma VK, Sethuraman G, Minz A. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol. 2008;74(3):238-40.

  20. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490-3.

  21. Clements WD, Diamond T, McCrory DC, Rowlands BJ. Biliary drainage in obstructive jaundice: experimental and clinical aspects. Br J Surg. 1993;80(7):834-42.

  22. Malik AA, Bari SU, Rouf KA, Wani KA. Pyogenic liver abscess: Changing patterns in approach. World J Gastrointest Surg. 2010;2(12):395-401.

  23. Huang CJ, Pitt HA, Lipsett PA, et al. Pyogenic hepatic abscess. Changing trends over 42 years. Ann Surg. 1996;223(5):600-7; discussion 607-9.

  24. Chung YF, Tan YM, Lui HF, et al. Management of pyogenic liver abscesses - percutaneous or open drainage? Singapore Med J. 2007;48(12):1158-65.

  25. Hope WW, Vrochides DV, Newcomb WL, Mayo-Smith WW, Iannitti DA. Optimal treatment of hepatic abscess. Am Surg. 2008;74(2):178-82.

  26. Malik AA, Bari SU, Rouf KA, Wani KA. Pyogenic liver abscess: Changing patterns in approach. World J Gastrointest Surg 2010;2(12): 395-401.




2020     |     www.medigraphic.com